AIRLINK 194.83 Decreased By ▼ -3.14 (-1.59%)
BOP 9.81 Decreased By ▼ -0.23 (-2.29%)
CNERGY 7.36 Increased By ▲ 0.07 (0.96%)
FCCL 38.58 Increased By ▲ 2.58 (7.17%)
FFL 16.45 Decreased By ▼ -0.46 (-2.72%)
FLYNG 27.54 Increased By ▲ 2.50 (9.98%)
HUBC 131.75 Decreased By ▼ -2.28 (-1.7%)
HUMNL 13.86 Decreased By ▼ -0.28 (-1.98%)
KEL 4.66 Decreased By ▼ -0.12 (-2.51%)
KOSM 6.66 Decreased By ▼ -0.28 (-4.03%)
MLCF 45.39 Increased By ▲ 0.41 (0.91%)
OGDC 213.99 Decreased By ▼ -4.24 (-1.94%)
PACE 6.86 Decreased By ▼ -0.08 (-1.15%)
PAEL 40.06 Decreased By ▼ -1.36 (-3.28%)
PIAHCLA 16.79 Decreased By ▼ -0.07 (-0.42%)
PIBTL 8.32 Decreased By ▼ -0.14 (-1.65%)
POWER 9.43 Increased By ▲ 0.04 (0.43%)
PPL 182.19 Decreased By ▼ -3.74 (-2.01%)
PRL 41.83 Increased By ▲ 0.56 (1.36%)
PTC 24.56 Decreased By ▼ -0.21 (-0.85%)
SEARL 102.53 Decreased By ▼ -2.12 (-2.03%)
SILK 1.00 Decreased By ▼ -0.01 (-0.99%)
SSGC 39.44 Decreased By ▼ -1.47 (-3.59%)
SYM 17.33 Decreased By ▼ -0.72 (-3.99%)
TELE 8.76 Decreased By ▼ -0.15 (-1.68%)
TPLP 12.75 Decreased By ▼ -0.09 (-0.7%)
TRG 65.40 Decreased By ▼ -1.20 (-1.8%)
WAVESAPP 11.11 Decreased By ▼ -0.19 (-1.68%)
WTL 1.70 Decreased By ▼ -0.08 (-4.49%)
YOUW 3.94 Decreased By ▼ -0.06 (-1.5%)
BR100 11,988 Decreased By -121.3 (-1%)
BR30 36,198 Decreased By -400.2 (-1.09%)
KSE100 113,443 Decreased By -1598.8 (-1.39%)
KSE30 35,635 Decreased By -564.3 (-1.56%)

British drugmaker GSK said on Thursday it would take a stake in Spero Therapeutics as part of a licensing agreement for the US-based drug developer’s experimental antibiotic for complicated urinary tract infections (cUTI).

GSK will pay $66 million upfront for the oral antibiotic tebipenem HBr and buy $9 million of Spero shares as part of the deal.

“Tebipenem HBr complements GSK’s infectious disease strategy and is consistent with our commitment to find value-enhancing opportunities to build a strong late-stage portfolio,” GSK’s chief commercial officer Luke Miels said in a statement.

In June, the US Food and Drug Administration declined to approve tebipenem, saying a late-stage study testing it was insufficient and an additional study would be required.

Spero has said it plans a new late-stage trial for 2023. The treatment has a fast track designation from the US drug agency for cUTI and acute pyelonephritis.

GSK agreed to purchase 7.45 million Spero shares at about $1.20805 per share, which will not exceed 19.99% ownership of Spero by GSK and its affiliates, the companies said.

Drug shortage: GSKCH rejects claims related to hoarding of Panadol

Spero’s shares closed down 6.7% at 82 cents on Wednesday, while GSK was marginally down in early trade on Thursday amid broader market weakness.

Spero developed tebipenem HBr with Japan’s Meiji Seika Pharma Co Ltd and is part of a subclass of antibiotics deemed to be effective in treating drug-resistant bacterial infections and is intended for adults with limited treatment options.

Comments

Comments are closed.